(Des-Thr7)-Glucagon, CAS: 1802078-28-9

(Des-Thr7)-Glucagon is a modified form of Glucagon and Glucagon receptor agonist. Glucagon is a peptide hormone, produced in the pancreas. Its effect is opposite to that of insulin, namely raising the concentration of glucose and fatty acids in the bloodstream. Thus, glucagon and insulin are part of a feedback system that keeps blood glucose homeostasis. Glucagon is a potential target for the therapeutic treatment of diabetes. It tends to form gel-like fibrillary aggregates that were found to be toxic through the activation of apoptotic signaling pathways. For research use only, do not use in humans!

(Des-Thr7)-Glucagon, CAS: 1802078-28-9 - Specifications

• Peptide sequence: H-HSQGTFSDYSKYLDSRRAQDFVQWLMNT-OH
• Amount: 0.5 mg net (50 x 10 µg) (AAA)
• Purity: >95% (HPLC-MS)
• Counterion: TFA
• Delivery Format: Freeze-dried in plastic vial
• Chemical formula: C149H218N42O47S
• MW (average): 3381.69
• Application(s): Diabetes research
• Condition(s)/Topic(s): Diabetes
• Standard Delivery Time: 2-5 days
• CAS: 1802078-28-9
• SMILES: N[C@@H](CC1=CNC=N1)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(NCC(N[C@@H]([C@@H](C)O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CC4=CC=C(O)C=C4)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC6=CNC7=C6C=CC=C7)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCCCN)=O)=O)=O)=O)CO)=O)=O)=O)=O)=O)=O

JPT’s Glucagon Peptides

Glucagon is a 29-amino acid polypeptide. Its primary sequence in humans is: NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH. Glucagon is a non-steroid peptide hormone produced in the pancreas. Its effect is opposite to that of insulin. Glucagon and insulin regulating blood glucose homeostasis making glucagon a potential target for the therapeutic treatment of diabetes. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.

• All peptides are made in Germany
• Bulk orders or custom peptide synthesis upon request
• Provision of freeze-dried aliquots for enhanced stability
• Proven track record
• Need the conjugated or modified peptide? Contact us!